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he Use of B-Type
atriuretic Peptides in Coronary
rtery Disease
tile or Futile?*
hristian Mueller, MD, FESC
asel, Switzerland
-type natriuretic peptides (BNP and N-terminal [NT]-
roBNP) have been shown to be extremely helpful in the
iagnosis, prognosis, and monitoring of therapy of patients
ith heart failure (HF) (1). These neurohormones are pre-
ominately secreted from the left and the right cardiac ventricle
n response to cardiac stress. The BNPs can be seen as
uantitative markers of HF summarizing the extent of systolic
nd diastolic left ventricular dysfunction, valvular dysfunction,
nd right ventricular dysfunction (1).
See page 205
Inspired by the overwhelming success in HF, several recent
tudies have addressed the use of BNP in the diagnosis,
rognosis, and management of patients with coronary artery
isease (CAD) (2–13).
iagnosis of stable CAD. In patients with stable CAD,
NPs are associated with the presence of myocardial isch-
mia, and angiographic disease severity (2–4). These find-
ngs have lead to the hypothesis that myocardial ischemia is
major trigger for the release of BNPs, and measurement of
ither baseline levels or exercise-induced increase of BNPs
ight be clinically helpful in the diagnosis of myocardial
schemia and CAD. Larger studies including consecutive
atients with suspected myocardial ischemia referred for
tress testing confirmed the association between BNPs and
yocardial ischemia. However, the diagnostic accuracy of
NPs for the detection of myocardial ischemia (65%) was
nly moderate. Still, the combination of exercise electrocar-
iogram (ECG) and BNPs seemed to slightly improve
iagnostic accuracy when compared with exercise ECG
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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cience Foundation, the Swiss Heart Foundation, the Novartis Foundation, the
rokus Foundation, Abbott, Brahms, Biosite, Roche, and the University of Basel.lone (5–7). The availability of more accurate noninvasive
ests like perfusion imaging and stress echocardiography
ight determine whether the diagnostic accuracy of BNPs
n this indication is high enough to justify clinical use.
mportantly, recent evidence suggested that selection bias
nd comorbidity significantly influence the accuracy of
NPs to diagnose stable CAD (8).
iagnosis of acute coronary syndrome (ACS). Cardiac
roponins (T and I) are currently the gold standard for the
iagnosis of myocardial infarction (MI). Unfortunately,
ardiac troponin is undetectable by current assays in periph-
ral blood within the first 3 to 6 h after the onset of chest
ain in MI (“troponin-blind” period). Preliminary data
uggested that BNPs might be clinically helpful in the early
iagnosis in patients with chest pain and no ST-segment
levation. In a large series of consecutive patients, the BNP
edian level at presentation was 204 pg/ml in MI, 78 pg/ml
n unstable angina, and 28 pg/ml in patients without ACS
9). At presentation, BNP was 100 pg/ml in 70% of
atients subsequently diagnosed with MI, while cardiac
roponin was elevated in only 50% of these patients
nitially. The specificity of BNP for MI was 69%. Several
ngoing studies will further elucidate the role of BNPs in
onjunction with novel high sensitivity cardiac troponin
ssays and possibly other markers including myeloperoxi-
ase for the early diagnosis of ACS.
rognosis of stable CAD and ACS. Multiple large cohort
tudies have consistently shown that BNPs are powerful
redictors of death in patients with stable CAD or ACS
10–12). Already 6 years ago, the TIMI (Thrombolysis In
yocardial Infarction) study group demonstrated that after
djustment for independent predictors of the long-term risk of
eath, patients in the 4th quartile of BNP had nearly 6 times
he risk of death as compared with patients in the 1st quartile.
single measurement of BNPs provides powerful information
or use in risk stratification across the spectrum of CAD. This
nding suggests that cardiac neurohormonal activation may be
unifying feature among CAD patients at high risk for death.
he data from the PEACE (Prevention of Events with
ngiotensin Converting Enzyme Inhibition) trial published in
his issue of the Journal extend this observation to low-risk
table CAD patients (12). The BNPs are also powerful
redictors for the development of HF and for the presence of
mpaired left ventricular systolic function. The accuracy of
NPs to detect a left ventricular ejection fraction of below 30%
as about 80% (11). In contrast, BNPs do not seem to predict
uture nonfatal MI (10–12).
anagement of CAD. The key question still remains to be
ddressed. How should BNPs influence patient management?
s there a specific medication or intervention that should be
nitiated based on elevated levels of BNPs? Obviously, BNPs
an only be used in conjunction with other clinical information
o guide management in patients with suspected or proven
AD. Despite this caveat, many clinicians including thisditorialist had hoped that B-type natriuretic peptides might
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Editorial Comment July 17, 2007:215–6elp to target angiotensin-converting enzyme (ACE) inhibi-
ors in CAD. As BNPs are closely associated with impaired left
entricular function and cardiac stress, those patients with
levated BNPs should derive particular benefit of ACE inhib-
tors. Unfortunately, neither the data from the PEACE trial
or the data from the HOPE (Heart Outcomes Prevention
valuation) study (S. Blankenberg, personal communication,
arch 4, 2007) support this hypothesis. In both randomized
ontrolled trials, no significant interaction between levels of
NPs and benefit from ACE inhibition was found.
High-risk patients with non–ST-segment elevation ACS
eem to derive maximal benefit from an early revsacularization
trategy (13,14). Could BNPs, therefore, be useful in the
election of initial ACS management? In the FRISC (Fragmin
nd fast Revascularization during InStability in Coronary
rtery disease) study, the mortality benefit from an early
nvasive strategy after non–ST-segment elevation ACS was
lightly greater when BNPs were higher. However, no inter-
ction between BNPs and the benefit of early revascularization
as observed in the TACTICS (Treat Angina with Aggrastat
nd Determine Cost of Therapy with an Invasive or Conser-
ative Strategy) study.
As BNPs predict both left ventricular systolic dysfunc-
ion and the risk of sudden cardiac death, it is reasonable
o assume that BNPs might be helpful to achieve a higher
ost effectiveness in our patient selection for implantation
f a defibrillator (15,16). Additional studies are necessary
o verify this hypothesis.
In conclusion, BNPs are very attractive tools also in
AD. However, we still have to learn how to make the best
linical use of the information provided.
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